Clinical Trial Update: Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload [Phase 3]

View source ↗

Summary

This Phase 3 expanded-access update describes deferasirox use for patients with congenital disorders of red blood cells and chronic iron overload, including tha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diamond-blackfan Anemia
• Myelofibrosis
• Sickle Cell Disease
• Thalassemia

Drugs mentioned

• Exjade (deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Thalassemia, Sickle Cell Disease | Phase 3 | Status: COMPLETED | Results posted: 2011-05-02